Safety and Feasibility of Endovascular Cooling Device in Patients With Hypothermic Cardiopulmonary Resuscitation
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hypothermic resuscitation is proven to be benefit to the cardiac origin cardiac arrest patients for it improve brain recovery dramatically. However, traditional cooling devices and methods, most external cooling methods, include ice blanket, cooling helmet, or ice packing lower the body temperature slowly or inefficiently which make many emergency physicians hesitate to perform hypothermic resuscitation. To improve and promote the practice of hypothermia resuscitation, more efficient temperature control method is necessary. We conduct this clinical trial to evaluate the safety and feasibility of internal cooling catheter and temperature regulatory device, which is approved by FDA in neurologic ICU for temperature control, in the cardiac arrest patients.
| Condition | Intervention |
|---|---|
|
Cardiac Arrest |
Device: ICY catheter, Thermoguard device |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
- complications and feasibility of endovascular cooling device
| Estimated Enrollment: | 15 |
| Study Start Date: | April 2005 |
| Estimated Study Completion Date: | October 2005 |
We recruited successful resuscitated nontraumatic cardiac arrest adult patients in the emergency department to evaluate the safety and feasibility of application those invasive internal temperature regulator devices. Internal cooling catheter, "ICY" , and thermal regulator device, "Coolguard 2000" are applied to the patients from femoral vein. WE definite 4 stages according to the temperature during the clinical trial: "The Cooling Phase", "Hypothermia phase", "Rewarming phase", and "Postrewarming phase". The temperature is lowed or elevated by the rate 0.5C/hr during the Cooling and Rewarming Phase, and it is maintained 33 +/- 1 C during hypothermia phase for 12 hours according to the comment of ACLS. To understand the safety and feasibility, regular blood sampling, bedside EEG and vital monitors, and special sheets are designed to document the every reasons, time points or every clinical events during hypothermia therapy. The patients is observed until rewarming finish for 48 hours or till death if expired during post-resuscitation hypothermia therapy.
Eligibility| Ages Eligible for Study: | 18 Years to 78 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Non-traumatic collapsed patients, whose pulsation continues and persists more than 5 minutes after return of spontaneous circulation from cardiopulmonary resuscitation and consciousness level is less than GCS 5 points.
Exclusion Criteria:
- 1. Age > 78 y/o or < 18 y/o 2. Core temperature< 34℃or > 38 ℃ after resuscitation 3. Pregnancy 4. Underline terminal malignancy disorder or refuse aggressive treatment cancer patient 5. Massive bleeding, known coagulopathy, or received regular anticoagulant medication 6. Persisted hypotension ( mean arterial BP < 60 mmHg) after resuscitation even under inotropic agents 7. No bed available in ICU
Contacts and Locations| Contact: Chiung Yuan Hsu, MD | 886-2-23123456 ext 2831 | dtemer01@yahoo.com.tw |
| Contact: Wen Jone Chen, PHD | 886-2-23123456 ext 2831 | jone@ha.mc.ntu.edu.tw |
| Taiwan | |
| NTUH | Recruiting |
| Taipei, Taiwan, 100 | |
| Contact: Chiung Yuan Hsu, MD 886-2-23123456 ext 5926 dtemer01@yahoo.com.tw | |
| Principal Investigator: | Wen Jone Chen, PHD | NTUH |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00154674 History of Changes |
| Other Study ID Numbers: | 25MD03 |
| Study First Received: | September 8, 2005 |
| Last Updated: | November 21, 2005 |
| Health Authority: | Taiwan: Department of Health |
Additional relevant MeSH terms:
|
Heart Arrest Heart Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013